Clinical trials: Molecular Targeted Therapies
Prostate Cancer
Maximal Androgen Depletion Followed by Randomization of Maximal Androgen Ablation With Molecular Targeted Therapies
You are being asked to take part in this study because you have prostate cancer that has spread to other parts of the body. This is an investigational study. Prednisone is FDA-approved and commercially available.
- Trial name
- NCT01254864
- Testing
- Abiraterone Acetate, Prednisone, Sunitinib
- Where
- United States
- Volunteers
- 190 people
- Sponsor
- M.D. Anderson Cancer Center
Renal Neoplasms, Targeted Molecular Therapy
A CpG-methylation-based Assay for Stratifying Stage III Clear Cell Renal Cell Carcinoma of Receiving Adjuvant Treatment
Whether patients with stage III clear cell renal cell carcinoma(ccRCC) should receive adjuvant targeted therapy or not is still on debate.
- Trial name
- NCT02688491
- Testing
- sunitinib
- Volunteers
- 300 people
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University
Central Nervous System Neoplasms, Pediatric Cancer
Pediatric Prospective Personalized Immune and Target Identification Trial
PPROSPERITIT is a prospective clinical study assessing the use of comprehensive molecular profiling to define the best matching targeted and immune treatment for relapsed, refractory or very high risk pediatric CNS tumors.
- Conditions
- Central Nervous System Neoplasms, Pediatric Cancer, GEN1 Gene Mutation, Tumor, Brain
- Trial name
- PPROSPERITIT (NCT04859543)
- Testing
- FoundationOneHeme
- Where
- 3 sites in Austria, Czechia
- Volunteers
- 80 people
- Sponsor
- Masaryk University
Hepatocellular Carcinoma
TACE Combined With ICIs Plus MTT After 125I Irradiation Stent Placement in HCC With Main PVTT.
Hepatocellular carcinoma (HCC) patients with Vp4 [main trunk] portal vein tumor thrombosis (PVTT) face a significantly poor prognosis, and current treatment options provide limited benefits.
- Trial name
- NCT06669377
- Where
- China
- Volunteers
- 444 people
- Sponsor
- Zhongda Hospital
Neuroendocrine Tumors,Gastroenteropancreatic
Cabozantinib and Lanreotide as Treatment for Gastroenteropancreatic Neuroendocrine Tumors
This is an Open-Label Phase I/II Study of daily cabozantinib plus lanreotide every 4 w eeks to treat advanced G1-2 gastroentero-pancreatic neuroendocrine tumor (GEP-NET) patients who failed to one line or more than one line of…
- Trial name
- NCT05048901
- Testing
- Cabozantinib, Lanreotide
- Where
- 11 sites in Taiwan
- Volunteers
- 49 people
- Sponsor
- National Health Research Institutes, Taiwan
Gastrointestinal Cancer, Gastric Cancer
NOMAD-GI: Molecular-guided Non-operative Management and Organ Preservation Strategy After Precision Therapy in Gastrointestinal Cancers
The NOMAD-GI study is a single-center, bidirectional cohort study designed to evaluate the safety and efficacy of molecular biomarker-guided non-operative management (NOM) and organ preservation strategies after precision therapy…
- Conditions
- Gastrointestinal Cancer, Gastric Cancer, Gastroesophageal Junction Cancer, Esophageal Cancer
- Trial name
- NOMAD-GI (NCT07775859)
- Volunteers
- 200 people
- Sponsor
- Peking University Cancer Hospital & Institute
Cholangiocarcinoma of the Extrahepatic Bile Duct, Gallbladder Cancer
Chemothetapy FORFIRINOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma
The purpose of this study is to evaluate the feasibility, efficacy and safety of FORFIRINOX in advanced or recurrent extrahepatic cholangiocarcinoma and gallbladder carcinoma.
- Trial name
- NCT03772132
- Testing
- mutation and signal pathway activation status analysis Drug: FORFIRINOX
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Metformin, Prediabetes
Metformin and Molecular Aging in Prediabetes
The incidence and prevalence of type 2 diabetes mellitus (T2DM) are increasing globally. The global prevalence of diabetes has nearly doubled since 1980, rising from 4.7% to 8.5% in the adult population.
- Trial name
- NCT07302932
- Testing
- Metformin treatment, Analyzed by qPCR for T/S ratio.
- Where
- India
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- Diabetes Foundation, India
Myelofibrosis (MF)
A New Diagnostic Algorithm to Non-invasively Track Fibrotic Changes in Myeloproliferative Neoplasms Based on C-C Chemokine Receptor 2 Detection. From Flow Cytometry to the Development of Targeted Positron Emission Tomography Molecular Imaging. Pre-clinical Studies and First In-human Proof of Concept
Chronic "Philadelphia-negative" myeloproliferative syndromes are chronic blood disorders. They include essential thrombocythemia, polycythemia vera, and myelofibrosis.
- Trial name
- GR-MPN (NCT07419178)
- Testing
- Diagnosis of MPN subtypes
- Where
- Italy
- Volunteers
- 265 people
- Sponsor
- Azienda Ospedaliero-Universitaria di Parma
Metastatic Solid Tumors (Any Localization)
Molecular Screening for Cancer Treatment Optimization
The primary objective of the study is to use high throughput molecular analysis (CGH Array and sequencing) to treat patients with metastatic cancer with targeted therapeutics in order to improve the progression free survival…
- Trial name
- MOSCATO 02 (NCT01566019)
- Testing
- Tumoral biopsy
- Where
- France
- Volunteers
- 2,150 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Epilepsy, Molecular Mechanisms of Pharmalogical Action, Protective Agents
A Phase 1 Positron Emission Tomography Study to Measure Cholesterol 24S-Hydroxylase Target Occupancy of TAK-935
The purpose of this study is to determine the brain cholesterol 24S-hydroxylase (CH24H) enzyme occupancy of TAK-935 after single oral dose in healthy participants using the positron emission tomography (PET) ligand [18F]MNI-792…
- Trial name
- NCT02497235
- Testing
- TAK-935, [18F]MNI-792 (tracer)
- Where
- United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Takeda
High-grade Serous Ovarian Cancer, Circulating Tumor DNA
CtDNA as a Novel Biomarker of Treatment Efficacy in Patients With Ovarian Cancer
This study is a prospective observational clinical trial. Patients who were diagnosed and treated for the first time were enrolled and their surgical pathology was confirmed to be high-grade serous ovarian cancer.
- Trial name
- NCT05027828
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Breast Cancer
Molecular Mechanisms of Clinical Resistance to Targeted Therapy Among Patients With Breast Cancer
The purpose of this study is to learn why certain drugs stop working in patients.In lab studies, tumors become resistant in several ways. Specific molecules seem to change and this may be why therapy stops working.
- Trial name
- NCT00897702
- Testing
- Blood draw, immunoenzyme technique, biopsy
- Where
- 7 sites in United States
- Volunteers
- 269 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Haematological Malignancy, Malignant Neoplasm
DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive Cancers
This clinical trial is looking at a drug called alectinib. Alectinib is approved as standard of care treatment for adult patients with certain types of lung cancer.
- Conditions
- Haematological Malignancy, Malignant Neoplasm, Lymphoproliferative Disorders, Neoplasms by Histologic Type
- Trial name
- DETERMINE (NCT05770037)
- Testing
- Alectinib
- Where
- 27 sites in United Kingdom
- Volunteers
- 30 people
- Sponsor
- Cancer Research UK
Reccurent/Metastatic Solid Tumor Disease
A Randomized Phase II Trial Comparing Therapy Based on Tumor Molecular Profiling Versus Conventional Therapy in Patients With Refractory Cancer
SHIVA is a proof of concept randomized phase II trial which compares two treatment strategies for patients with refractory cancer.
- Trial name
- SHIVA (NCT01771458)
- Testing
- Targeted therapy based on molecular profiling : Imatinib, Tumor biopsy, Standard Chemotherapy
- Where
- 8 sites in France
- Volunteers
- 742 people
- Sponsor
- Institut Curie
Breast Cancer Female
Molecular Imaging of HER2 Expression in HER2-positive Breast Cancer Using 99mTc-ADAPT6 vs 99mTc-DARPinG3
An open-label, single center study with 99mTc-ADAPT6 and 99mTc-DARPinG3 SPECT and biopsies of primary tumour in HER2-positive Breast Cancer before system (chemo/targeted) therapy, where the primary endpoint of the study is to…
- Trial name
- NCT05376644
- Testing
- 99mTc-ADAPT6, 99mTc-DARPinG3
- Where
- Russia
- Volunteers
- 15 people
- Sponsor
- Tomsk National Research Medical Center of the Russian Academy of Sciences
Rare Cancers, Cholangiocarcinoma
TCF-001 TRACK (Target Rare Cancer Knowledge) Study
This open label, non-randomized, multi-center, pragmatic study aims to establish whether patients with rare tumors can benefit from matched molecular therapy as dictated by their next-generation sequencing (NGS) results.
- Conditions
- Rare Cancers, Cholangiocarcinoma, Cancer of Unknown Primary Site
- Trial name
- TRACK (NCT04504604)
- Testing
- FoundationOne CDx and FoundationOne Liquid CDx
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- TargetCancer Foundation
Lung Cancer, Non-Small Cell Lung Cancer
Molecular Profiling Project
In this study, the investigators plan to undertake comprehensive molecular profiling of "actionable" alterations in lung cancer specimens in order to determine the prevalence of each genetic subtype in the local population.
- Trial name
- NCT04025515
- Where
- 10 sites in Brunei, Hong Kong and 4 more
- Volunteers
- 500 people
- Sponsor
- National Cancer Centre, Singapore
Haematological Malignancy, Melanoma
DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.
This clinical trial is looking at a combination of drugs called vemurafenib and cobimetinib. Vemurafenib is approved as standard of care for adult patients with unresectable or metastatic melanoma.
- Conditions
- Haematological Malignancy, Melanoma, Thyroid Cancer, Papillary, Ovarian Neoplasms
- Trial name
- DETERMINE (NCT05768178)
- Testing
- Vemurafenib, Cobimetinib
- Where
- 16 sites in United Kingdom
- Volunteers
- 30 people
- Sponsor
- Cancer Research UK
Biliary Tract Cancer, Anti-PD-1 Therapy
Camrelizumab Combined With Apatinib and Capecitabine in Patients With Advanced Biliary Tract Cancer.
Biliary tract cancer (BTC) is a series of rare malignancies with poor overall prognosis. Radical surgery the preferred treatment option, but most patients have lost the opportunity of surgery at the time of diagnosis.
- Conditions
- Biliary Tract Cancer, Anti-PD-1 Therapy, Targeted Molecular Therapy, Capecitabine
- Trial name
- NCT04720131
- Testing
- Camrelizumab, apatinib, Capecitabine
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Beijing Friendship Hospital